# Cannabis Use Patterns in First Episode Psychosis and Schizophrenia: A Scoping Review and Case Series > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-use-patterns-schizophrenia-clinical-review/ > **Published:** 2026-03-28T08:17:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:36:20-04:00 > **Clinical Summary:** Explore cannabis use patterns schizophrenia and their impact on psychosis and schizophrenia in this clinical scoping review and case series. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic PsychosisSchizophreniaThcAssessmentMental Health Journal Journal of psychiatric research Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters This scoping review highlights critical gaps in how we measure and understand [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns in patients with psychosis and schizophrenia. With [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) expanding and product potency increasing, clinicians need better frameworks to assess and monitor [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in this vulnerable population. Clinical Summary This scoping review examined 10 studies (2,631 participants) published after 2016 to characterize cannabis use patterns in schizophrenia spectrum disorders, supplemented by a case series from recent inpatient data. The review found significant methodological inconsistencies across studies, with no standardized measurement approaches and wide variation in reported use frequency and quantity (0.6-3.4 joints per day). Most studies showed at least a minority of participants using cannabis very frequently, but none were specifically designed to track cannabis use patterns over time. The lack of standardized assessment tools represents a major limitation for both research and [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). Dr. Caplan’s Take “What strikes me most is how poorly equipped we are to meaningfully assess cannabis use in patients with psychosis – we’re flying blind with inconsistent measures while cannabis products become more potent. This review confirms what I see clinically: we need standardized assessment tools that account for modern cannabis products and consumption patterns.” Clinical Perspective 🧠 Clinicians should recognize that current cannabis assessment methods may be inadequate for patients with psychosis. Consider implementing more detailed cannabis use histories that include product type, THC potency, and consumption frequency rather than relying on binary use/non-use categories. This population requires enhanced monitoring given the established risks of cannabis use in psychotic disorders. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20use%20patterns%20in%20first%20episode%20psychosis%20and%20schizophrenia%3A%20A%20scoping%20re...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41795326/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41795326/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20use%20patterns%20in%20first%20episode%20psychosis%20and%20schizophrenia%3A%20A%20scoping%20re...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41795326/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41795326/](https://pubmed.ncbi.nlm.nih.gov/41795326/) Table of Contents - [FAQ](#FAQ)[How much cannabis do patients with schizophrenia typically use?](#How_much_cannabis_do_patients_with_schizophrenia_typically_use) - [Should I be concerned about cannabis use in patients with first-episode psychosis?](#Should_I_be_concerned_about_cannabis_use_in_patients_with_first-episode_psychosis) - [How should I assess cannabis use in my patients with psychotic disorders?](#How_should_I_assess_cannabis_use_in_my_patients_with_psychotic_disorders) - [Is the relationship between cannabis and psychosis well-established?](#Is_the_relationship_between_cannabis_and_psychosis_well-established) - [What are the clinical implications of increasing cannabis legalization for psychotic disorders?](#What_are_the_clinical_implications_of_increasing_cannabis_legalization_for_psychotic_disorders) - [Related](#Related) ## FAQ #### How much cannabis do patients with schizophrenia typically use? Cannabis use patterns vary widely among patients with schizophrenia spectrum disorders, with reported usage ranging from 0.6 to 3.4 joints per day. At least a minority of patients in each study used cannabis very frequently, indicating significant consumption levels in this population. #### Should I be concerned about cannabis use in patients with first-episode psychosis? Yes, cannabis use is associated with both the development of psychosis and symptom relapse in patients with schizophrenia spectrum disorders. This is particularly concerning as cannabis products have increased in potency and legalization has expanded access. #### How should I assess cannabis use in my patients with psychotic disorders? Current research shows that cannabis measurement methodology varies widely and most studies don’t use standardized measures. Clinicians should systematically assess quantity, frequency, and type of cannabis use, though standardized assessment tools for this population need further development. #### Is the relationship between cannabis and psychosis well-established? Yes, there is established evidence linking cannabis use to psychosis development and symptom relapse in schizophrenia spectrum disorders. However, this scoping review found limited recent research specifically characterizing cannabis use patterns over time in this vulnerable population. #### What are the clinical implications of increasing cannabis legalization for psychotic disorders? As U.S. states continue to legalize cannabis and product potency increases, clinicians need better understanding of cannabis use patterns in patients with schizophrenia spectrum disorders. This is crucial for developing appropriate monitoring and intervention strategies for this high-risk population. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Cannabis use patterns in first episode psychosis and schizophrenia: A scoping review and case series.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41795326/”, “about”: “journal psychiatric research [clinical study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) cannabis”, “isPartOf”: “Journal of psychiatric research”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis-Induced Psychosis & Schizophrenia Risk: Key Research](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) An in-depth review of the evidence linking cannabis use to psychosis and schizophrenia risk, highlighting clinical implications. [Read More](https://cedclinic.com/cannabis-induced-psychosis-schizophrenia-progression-insights/) [Cannabis Use Disorder Treatment Europe Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) A comprehensive overview of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) treatments in Europe, relevant for managing psychosis-related cannabis use. [Explore Treatments](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) [The Effect of Cannabis Use on the Time Course of Positive and Negative Affect in the Daily Life of Youth](https://cedclinic.com/cannabis-effects-youth-daily-mood-patterns/) Study examining how cannabis use influences mood fluctuations, providing context for psychosis symptom management. [Learn More](https://cedclinic.com/cannabis-effects-youth-daily-mood-patterns/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).